Zymeworks

ZYME

Market cap $1.39B

The mean of analysts' price targets for Zymeworks (ZYME) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET).

Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer. Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks' broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519.

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately.

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer.

I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but ZYME is pivoting to a trispecific T-cell engager, ZW209, for improved safety and efficacy. ZW191 and ZW251 ADCs leverage proprietary TOPO1i payloads, targeting large, high-need markets in ovarian and liver cancer with strong scientific rationale.

Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.

Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its decision to voluntarily discontinue clinical development of ZW171, a T cell engager designed to target gynecological, thoracic, and digestive system cancers.